This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (17)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Terry A. Jacobson, MD; Margaret M. Chin, PharmD; Charles L. Curry, MD; Valery Miller, MD; Vasilius Papademetriou, MD; Robert C. Schlant, MD; John C. LaRosa, MD

Arch Intern Med. 1995;155(17):1900-1906.

Abstract
Background
Coronary artery disease strikes early and may prove particularly severe in persons of African-American descent. Therefore, we studied the lipid-lowering efficacy and safety of pravastatin sodium (20 mg/d), a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in 245 African-American patients with primary hypercholesterolemia.

Methods
After 4 weeks on an American Heart Association phase I low-fat diet, patients were randomized in a double-blind manner to either pravastatin or placebo in a 3:1 ratio.

Results
After 12 weeks of pravastatin treatment, low-density lipoprotein cholesterol levels declined 25.8%, total cholesterol levels 20.3%, and triglyceride levels 6.2%, while high-density lipoprotein cholesterol levels remained essentially unchanged. Overall, 72% of pravastatin-treated patients achieved reductions in low-density lipoprotein cholesterol level in excess of 20%, and 44% attained declines in excess of 30% (both P<.01 vs placebo). Pravastatin was generally well tolerated in this population, with one patient (0.5%) exhibiting a reversible myopathy with creatine kinase elevations to 10 times the upper limit of normal. No substantial elevations of aminotransferase levels of two to three times the upper limit of normal occurred in either the pravastatin or the placebo group. Drug compliance was high, exceeding 90%.

Conclusion
Pravastatin appears to be an effective and safe lipid-lowering agent and is the first 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor to be studied extensively in this underrepresented population.

(Arch Intern Med. 1995;155:1900-1906)

Author Affiliations
From the Department of Medicine, Emory University School of Medicine, Atlanta, Ga (Drs Jacobson and Schlant); Philadelphia (Pa) College of Pharmacy and Science (Dr Chin); Division of Cardiovascular Disease, Howard University Hospital, Washington, DC (Dr Curry); Lipid Research Clinic, George Washington Medical Center, Washington, DC (Drs Miller and LaRosa); and Veterans Affairs Medical Center, Washington, DC (Dr Papademetriou).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Effect of Pretreatment With Statins on Ischemic Stroke Outcomes
Reeves et al.
Stroke 2008;39:1779-1785.
ABSTRACT | FULL TEXT  

Effectiveness of Ezetimibe Added to Ongoing Statin Therapy in Modifying Lipid Profiles and Low-Density Lipoprotein Cholesterol Goal Attainment in Patients of Different Races and Ethnicities: A Substudy of the Ezetimibe Add-On to Statin for Effectiveness Trial
Pearson et al.
Mayo Clin Proc. 2006;81:1177-1185.
ABSTRACT | FULL TEXT